Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.

World J Surg Oncol · 2021 · PMC7986386 · PMID 33752677

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

There were significant differences in the use of the CDDP plus gemcitabine or S-1 and FOLFIRINOX and marginally significant difference in the use of GnP between the UFS and GS groups (Table 2 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.